NEW: A compound from the Hergenrother/Shapiro collaboration has been licensed and is advancing toward treatment of breast cancer.

Unprecedented Compound Takes a Step Toward Breast Cancer Clinical Trials Estrogen receptor-positive breast cancer is the most common form of breast cancer, affecting approximately 75% of breast cancer patients. In advanced and metastatic form, it is lethal, claiming the lives of nearly 350,000 individuals annually. Presently, no drug is able to eradicate these advanced tumors. […]

Hergenrother Lab
261 Roger Adams Lab
600 S. Mathews Avenue
Urbana, IL 61802
Email: hergenro@illinois.edu